MorphoSys Granted Fifth US Patent for its Core Antibody Technology

Oct 09, 2007
By BioPharm International Editors

The US Patent & Trademark Office has issued the fifth US patent to MorphoSys AG (Munich, Germany) stemming from MorphoSys’s base HuCAL (human combinatorial antibody library) patent family, providing extended protection to MorphoSys’s core technology. The new patent (US 7,264,963) captures HuCAL’s modular design at the DNA level, providing solid product claim protection in the US.

MorphoSys’s HuCAL libraries comprise highly diverse, fully human synthetic antibodies that are highly engineerable through their modular CDR design. In its most advanced marketed version, HuCAL provides access to fully human antibodies as research tools, diagnostics, and therapeutics. The US Patent Office issued the first HuCAL patent in 2001, and patents have also been granted in Australia and at the European Patent Office. To date, MorphoSys has been granted more than 15 patents and more than 40 applications are pending worldwide.

MorphoSys release